Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa

Detalles Bibliográficos
Autores principales: Gray, Glenda, Collie, Shirley, Goga, Ameena, Garrett, Nigel, Champion, Jared, Seocharan, Ishen, Bamford, Lesley, Moultrie, Harry, Bekker, Linda-Gail
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9093716/
https://www.ncbi.nlm.nih.gov/pubmed/35507482
http://dx.doi.org/10.1056/NEJMc2202061
_version_ 1784705394021498880
author Gray, Glenda
Collie, Shirley
Goga, Ameena
Garrett, Nigel
Champion, Jared
Seocharan, Ishen
Bamford, Lesley
Moultrie, Harry
Bekker, Linda-Gail
author_facet Gray, Glenda
Collie, Shirley
Goga, Ameena
Garrett, Nigel
Champion, Jared
Seocharan, Ishen
Bamford, Lesley
Moultrie, Harry
Bekker, Linda-Gail
author_sort Gray, Glenda
collection PubMed
description
format Online
Article
Text
id pubmed-9093716
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Massachusetts Medical Society
record_format MEDLINE/PubMed
spelling pubmed-90937162022-05-23 Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa Gray, Glenda Collie, Shirley Goga, Ameena Garrett, Nigel Champion, Jared Seocharan, Ishen Bamford, Lesley Moultrie, Harry Bekker, Linda-Gail N Engl J Med Correspondence Massachusetts Medical Society 2022-05-04 /pmc/articles/PMC9093716/ /pubmed/35507482 http://dx.doi.org/10.1056/NEJMc2202061 Text en Copyright © 2022 Massachusetts Medical Society. All rights reserved. This article is made available via the PMC Open Access Subset for unrestricted re-use, except commercial resale, and analyses in any form or by any means with acknowledgment of the original source. PMC is granted a license to make this article available via PMC and Europe PMC, subject to existing copyright protections.
spellingShingle Correspondence
Gray, Glenda
Collie, Shirley
Goga, Ameena
Garrett, Nigel
Champion, Jared
Seocharan, Ishen
Bamford, Lesley
Moultrie, Harry
Bekker, Linda-Gail
Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa
title Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa
title_full Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa
title_fullStr Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa
title_full_unstemmed Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa
title_short Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa
title_sort effectiveness of ad26.cov2.s and bnt162b2 vaccines against omicron variant in south africa
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9093716/
https://www.ncbi.nlm.nih.gov/pubmed/35507482
http://dx.doi.org/10.1056/NEJMc2202061
work_keys_str_mv AT grayglenda effectivenessofad26cov2sandbnt162b2vaccinesagainstomicronvariantinsouthafrica
AT collieshirley effectivenessofad26cov2sandbnt162b2vaccinesagainstomicronvariantinsouthafrica
AT gogaameena effectivenessofad26cov2sandbnt162b2vaccinesagainstomicronvariantinsouthafrica
AT garrettnigel effectivenessofad26cov2sandbnt162b2vaccinesagainstomicronvariantinsouthafrica
AT championjared effectivenessofad26cov2sandbnt162b2vaccinesagainstomicronvariantinsouthafrica
AT seocharanishen effectivenessofad26cov2sandbnt162b2vaccinesagainstomicronvariantinsouthafrica
AT bamfordlesley effectivenessofad26cov2sandbnt162b2vaccinesagainstomicronvariantinsouthafrica
AT moultrieharry effectivenessofad26cov2sandbnt162b2vaccinesagainstomicronvariantinsouthafrica
AT bekkerlindagail effectivenessofad26cov2sandbnt162b2vaccinesagainstomicronvariantinsouthafrica

Ejemplares similares